儿童急性淋巴细胞白血病无颅脑放疗治疗的中枢神经系统控制预后因素
该研究分析中国儿童癌症组ALL-2015方案治疗的7640例儿童ALL患者,方案不含预防性颅脑放疗。5年无事件生存率80.3%,总生存率91.1%,孤立性中枢神经系统复发累积风险1.9%。男性、B-ALL中BCR-ABL1融合及T-ALL中初诊白细胞≥50×10⁹/L为独立危险因素,而全静脉麻醉和脑脊液流式细胞术检查与更低复发相关。
要点
- 无颅脑放疗方案下孤立性中枢神经系统复发累积风险为1.9%。
- B-ALL中BCR-ABL1融合及T-ALL中初诊白细胞≥50×10⁹/L增加孤立性中枢神经系统复发风险。
- 鞘内治疗时使用全静脉麻醉及诊断性脑脊液流式细胞术检查可能改善中枢神经系统控制。
核心结论
- 在无预防性颅脑放疗的儿童ALL方案中,孤立性中枢神经系统复发累积风险为1.9%,总体中枢神经系统控制较好。
- 男性、B-ALL中BCR-ABL1融合、T-ALL中初诊白细胞≥50×10⁹/L是孤立性中枢神经系统复发的独立危险因素。
研究设计与样本
- 研究分析了2015至2019年间在中国儿童癌症组ALL-2015方案治疗的7640例连续儿童ALL患者。
- 方案特点为常规缓解诱导前预治疗地塞米松及后续风险导向治疗,包括16至22次三联鞘内注射,不含预防性颅脑放疗。
主要发现
- 5年无事件生存率为80.3%(95%CI 78.9-81.7),总生存率为91.1%(95%CI 90.1-92.1)。
- 孤立性中枢神经系统复发累积风险为1.9%(95%CI 1.5-2.3),任何中枢神经系统复发累积风险为2.7%(95%CI 2.2-3.2)。
临床怎么用
- 对于无颅脑放疗的儿童ALL,应关注男性、B-ALL中BCR-ABL1融合及T-ALL中初诊白细胞≥50×10⁹/L等高危因素以强化中枢神经系统控制。
- 鞘内治疗时考虑使用全静脉麻醉,并对诊断性脑脊液进行流式细胞术检查,可能降低孤立性中枢神经系统复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To identify the prognostic factors that are useful to improve central nervous system (CNS) control in children with acute lymphoblastic leukemia (ALL), we analyzed the outcome of 7640 consecutive patients treated on Chinese Children's Cancer Group ALL-2015 protocol between 2015 and 2019. This protocol featured prephase dexamethasone treatment before conventional remission induction and subsequent risk-directed therapy, including 16 to 22 triple intrathecal treatments, without prophylactic cranial irradiation. The 5-year event-free survival was 80.3% (95% confidence interval [CI], 78.9-81.7), and overall survival 91.1% (95% CI, 90.1-92.1). The cumulative risk of isolated CNS relapse was 1.9% (95% CI, 1.5-2.3), and any CNS relapse 2.7% (95% CI, 2.2-3.2). The isolated CNS relapse rate was significantly lower in patients with B-cell ALL (B-ALL) than in those with T-cell ALL (T-ALL) (1.6%; 95% CI, 1.2-2.0 vs 4.6%; 95% CI, 2.9-6.3; P < .001). Independent risk factors for isolated CNS relapse included male sex (hazard ratio [HR], 1.8; 95% CI, 1.1-3.0; P = .03), the presence of BCR-ABL1 fusion (HR, 3.8; 95% CI, 2.0-7.3; P < .001) in B-ALL, and presenting leukocyte count ≥50×109/L (HR, 4.3; 95% CI, 1.5-12.2; P = .007) in T-ALL. Significantly lower isolated CNS relapse was associated with the use of total intravenous anesthesia during intrathecal therapy (HR, 0.2; 95% CI, 0.04-0.7; P = .02) and flow cytometry examination of diagnostic cerebrospinal fluid (CSF) (HR, 0.2; 95% CI, 0.06-0.6; P = .006) among patients with B-ALL. Prephase dexamethasone treatment, delayed intrathecal therapy, use of total intravenous anesthesia during intrathecal therapy, and flow cytometry examination of diagnostic CSF may improve CNS control in childhood ALL. This trial was registered with the Chinese Clinical Trial Registry (ChiCTR-IPR-14005706).
引用
- Tang J, Yu J, Cai J, et al. Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation. Blood. 2021. PMID: 33684941. doi:10.1182/blood.2020010438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。